Trial Profile

Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MTX 101 Mozart Therapeutics (Primary)
Indications Coeliac disease; Type 1 diabetes mellitus
Focus Adverse reactions; First in man
Sponsors Mozart Therapeutics

Most Recent Events

17 Mar 2025 According to a Mozart Therapeutics media release, first patients with type 1 diabetes and celiac disease have been enrolled in Part B of the study, which is being conducted at multiple clinical sites in Australia.
17 Mar 2025 According to a Mozart Therapeutics media release, company plans to present full data from the Phase 1a study at upcoming medical symposia.
17 Mar 2025 Results presented in a Mozart Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com